Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 2Breast 2

Conditions

Prostatic Neoplasms 2Hot Flashes 1Carcinoma, Intraductal, Noninfiltrating 1Breast Cancer Early Stage Breast Cancer (Stage 1-3) 1

Interventions

Cisplatin 1514Carboplatin 1416Cyclophosphamide 1359Gemcitabine 1235Bevacizumab 1223Paclitaxel 1210Radiotherapy 1173Docetaxel 1079pembrolizumab 1026Oxaliplatin 934Capecitabine 898Fluorouracil 832Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 665Etoposide 660Irinotecan 622Leucovorin 574Pemetrexed 508Drug Therapy 491Cetuximab 481Trastuzumab 467Cytarabine 466Magnetic Resonance Spectroscopy 457Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 407Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × fezolinetant × Clear all
NCT06617455 2026-05-06

VEnT

University of Michigan Rogel Cancer Center

Phase 2 Terminated
9 enrolled
Breast

Carcinoma, Intraductal, Noninfiltrating

NCT06917313 2026-05-06

FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

Yale University

Phase 2 Recruiting
92 enrolled
Breast

Breast Cancer Early Stage Breast Cancer (Stage 1-3)

NCT07568236 2026-05-05

A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)

Chinese University of Hong Kong

Phase 2 Not yet recruiting
54 enrolled
Genitourinary

Prostatic Neoplasms

NCT06972875 2026-02-05

FLASH

University of Vermont

Phase 2 Recruiting
32 enrolled
Genitourinary

Prostatic Neoplasms, Hot Flashes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡